8 analysts have expressed a variety of opinions on Nurix Therapeutics NRIX over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

On Wednesday, Stifel analysts increased the price target on Nurix Therapeutics Inc . (NASDAQ:NRIX) shares to $36.00, up from the previous target of $34.00, while reaffirming their Buy rating on ...

Gilead isn’t the first major partner for Nurix either. In 2015 Celgene signed up with the biotech in a deal focused on harnessing the protein degradation system to find drugs that may improve ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $35.00. Jeet Mukherjee has given his Buy ...

Nurix Therapeutics has a fifty-two week low of $8.11 and a fifty-two week high of $29.56. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.53 and a beta of 2.14.

SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) – Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...